The Clinical Trial of Difference Between Formaderm Lidocaine and Formaderm Dermal Filler Injection

The goal of this clinical trial is to evaluate the safety and efficacy of Formaderm Lidocaine to the correction of nasolabial folds wrinkle and reduction of pain immediately after treatment. The main questions it aims to answer are:

1. The pain score assessed using Visual Analog Pain Scale(VAS) and Thermometer Pain Scale(TPS).
2. The facial wrinkle assessed using Wrinkle Severity Rating Scales(WSRS).
3. The treatment improvement assessed using Global Aesthetic Improvement Scale (GAIS).
4. Safety Indicators of which incidences on the day of the injection or after the injection.

Participants will be self-controlled and randomized for same period,

• received both trial product and control product at the same time.
• re-visited on Day 14 and Day 30 after injection.

The researchers will compare whether Formaderm Lidocaine is superior to Formaderm Dermal Filler Injection (without lidocaine) in terms of pain relief experienced by subjects during injection.

Study Overview

• Status: Completed
• Conditions: Lidocaine; Hyaluronic Acid; Dermal Fillers
• Intervention / Treatment: Device: Formaderm Dermal Filler Injection; Device: Formaderm Lidocaine

Detailed Description

This is a two-center, randomized, self-controlled, double-blind trial. Each subject received the trial product and control product injections at the same time to assess the safety and efficacy of Formaderm Lidocaine, which is a hyaluronic acid dermal filler injection with lidocaine.

• Study Type: Interventional
• Enrollment (Actual): 42
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Taiwan
  • Taiwan (r.o.c.)
    • Taipei City, Taiwan (r.o.c.), Taiwan, 100
      • National Taiwan University Hospital
    • Taoyuan City, Taiwan (r.o.c.), Taiwan, 33383
      • TRI-Service General Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Subjects are aged 20-65 years old of both sexes.
• Subjects who have bilateral nasolabial folds with 3-4 points of WSRS baseline measurement.
• Subjects who are willing to undergo the dermal filling therapy.
• The facial skin is healthy, without any disease that possibly interferes with skin aging status assessment, i.e., facial nerve paralysis
• The subject is willing to avoid undergoing other cosmetic treatment and surgery for the entire duration of investigation.
• The subject is willing to adhere to the protocol and sign the Informed Consent before the investigation.

Exclusion Criteria:

• Women subjects who are pregnant, breastfeeding, planning to become pregnant, and not willing to take contraception during the trial period.
• Subjects with history of allergies to hyaluronic acid.
• Subjects with history of allergies to lidocaine or amide-type local anesthetics.
• Those who are suffering from immunity related disorder.
• Those who are suffering from a mental disease.
• Those who are suffering from alcohol use disorder.
• Those who have severe heart, kidney, liver or respiratory system disorder.
• Those who have localized infection, severe skin disease, inflammation, tumor or other related disease in the nasolabial fold area.
• Those with a scar-prone constitution, prone to scar formation, hypertrophic scars or keloids.
• Those with coagulation disorder
• Patients undergoing anticoagulant treatment or taking non-steroidal anti-inflammatory drug(NSAID) within the past 1 week before screening.
• Those with permanent implants in the nasolabial fold area.
• Those who have undergone chemical peels treatment within the last 4 weeks before screening.
• Those who have undergone cosmetic treatment or surgery prior in the nasolabial fold area within the last 24 weeks before screening, such as botox injections, laser treatment of dermal lesions, or plastic surgery.
• Those who have undergone nasolabial fold augmentation treatment within the past 52 weeks before screening, such as autologous fat grafting, hyaluronic acid implants or collagen implants.
• Those who have joined other clinical trials within the past 12 weeks before screening (except for the clinical trials of questionnaire or sample collection)
• Those who are unable to comply with re-visit schedule.
• Those whose medication and medical conditions are deemed unfit for inclusion in the research based on the judgment of the researcher.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Formaderm Lidocaine; Formaderm Lidocaine was randomly administered either side of subjects' facial areas once.The injection volume was limited to 2c.c.	Device: Formaderm Lidocaine; Dermal filler injection to facial areas
Active Comparator: Formaderm Dermal Filler Injection; Formaderm Dermal Filler Injection was randomly administered either side of subjects' facial areas once.The injection volume was limited to 2c.c.	Device: Formaderm Dermal Filler Injection; Dermal filler injection to facial areas

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Immediately Pain Score Using Visual Analog Pain Scale(VAS)	Assess the pain score immediately after application of Formaderm Lidocaine and Formaderm Dermal Filler Injection(without Lidocaine) at nasolabial fold by utilizing subject reported visual analog pain scale (1 = no pain, 10 = excruciating pain).	immediately after injection

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pain Score Using Visual Analog Pain Scale(VAS)	Assess the pain score after 15, 30, 45, 60 minutes of application of Formaderm Lidocaine and Formaderm Dermal Filler Injection(without Lidocaine) at nasolabial fold by utilizing subject reported visual analog pain scale (1 = no pain, 10 = excruciating pain).	15, 30, 45, 60 minutes after injection
Pain Score Using Thermometer Pain Scale(TPS)	Assess the pain score by the physician according to subjects' response immediately after application of Formaderm Lidocaine and Formaderm Dermal Filler Injection(without Lidocaine) at nasolabial fold. Thermometer Pain Scale(TPS) is scored from 0= no pain, to 10= worst possible pain.	immediately after injection
Wrinkle Severity Rating Scales(WSRS) improvement ratio	Based on the photographs, blinded physician rated the score of WSRS (Wrinkle Severity Rating Scales) for both group respectively. The difference of WSRS between baseline and day 14 and 30 were calculated. A positive value indicated "effective" improvement; while a value of 0 or a negative value was regarded as "ineffective" treatment. And the WSRS improvement ratio was defined as the effective improvement ratio of either group. The WSRS is a 5-grade instrument for facial wrinkle, Grade 1(absent, no visible nasolabial fold;continuous skin line ) to Grade 5(extreme, extremely deep and long nasolabial fold, detrimental to facial appearance;2-4mm visible V-shaped fold when stretched; unlikely to have satisfactory correction with injectable implant alone)	Baseline, Day 14, Day 30
GAIS score assessed by physician	Compared with the baseline photographs, blinded physician rated the class of GAIS(Global Aesthetic Improvement Scale) on Day 14 and Day 30 from 5(exceptional improvement, excellent corrective result) to 1(worsened patient, the appearance has worsened compared with the original condition) for both group respectively.	Day 14, Day 30
GAIS score assessed by subjects	Compared with the baseline photographs, the subjects rated the class of GAIS(Global Aesthetic Improvement Scale) on Day 14 and Day 30 from 5(exceptional improvement, excellent corrective result) to 1(worsened patient, the appearance has worsened compared with the original condition) for both group respectively.	Day 14, Day 30
Incidence of Treatment-related Adverse Events	The adverse events are defined as any unfavorable sign occurrence in a subject after treatment. The investigator assesses the severity and the relationship of each event to the use of the study device.	Day 0 to Day 30

Collaborators and Investigators

• Sponsor: Maxigen Biotech Inc.

Study record dates

Study Major Dates

• Study Start (Actual): August 4, 2020
• Primary Completion (Actual): November 26, 2020
• Study Completion (Actual): June 24, 2021

Study Registration Dates

• First Submitted: June 29, 2023
• First Submitted That Met QC Criteria: June 29, 2023
• First Posted (Actual): July 7, 2023

Study Record Updates

• Last Update Posted (Actual): July 7, 2023
• Last Update Submitted That Met QC Criteria: June 29, 2023
• Last Verified: June 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Anti-Arrhythmia Agents; Central Nervous System Depressants; Peripheral Nervous System Agents; Sensory System Agents; Anesthetics; Membrane Transport Modulators; Anesthetics, Local; Voltage-Gated Sodium Channel Blockers; Sodium Channel Blockers; Lidocaine
• Other Study ID Numbers: 0176TC10

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No